Literature DB >> 16912200

Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma.

Christine H Chung1, Joel S Parker, Kim Ely, Jesse Carter, Yajun Yi, Barbara A Murphy, K Kian Ang, Adel K El-Naggar, Adam M Zanation, Anthony J Cmelak, Shawn Levy, Robbert J Slebos, Wendell G Yarbrough.   

Abstract

Gene expression signatures generated from DNA microarray analyses have shown promise as predictive biomarkers of clinical outcome. In this study, we determined a high-risk signature for disease recurrence using formalin-fixed head and neck squamous cell carcinoma (HNSCC) tumors and compared the results with an independent data set obtained from fresh frozen tumors. We also showed that genes involved in epithelial-to-mesenchymal transition (EMT) and nuclear factor-kappaB (NF-kappaB) signaling deregulation are the most prominent molecular characteristics of the high-risk tumors. Gene expression was determined in 40 samples, including 34 formalin-fixed tissues and 6 matched frozen tissues, from 29 HNSCC patients. A 75-gene list predictive of disease recurrence was determined by training on the formalin-fixed tumor data set and tested on data from the independent frozen tumor set from 60 HNSCC patients. The difference in recurrence-free survival (RFS) between the high-risk versus low-risk groups in the training and test sets was statistically significant (P = 0.002 and 0.03, respectively, log-rank test). In addition, the gene expression data was interrogated using Gene Set Enrichment Analysis to determine biological significance. The most significant sets of genes enriched in the high-risk tumors were genes involving EMT, NF-kappaB activation, and cell adhesion. In conclusion, global gene expression analysis is feasible using formalin-fixed tissue. The 75-gene list can be used as a prognostic biomarker of recurrence, and our data suggest that the molecular determinants of EMT and NF-kappaB activation can be targeted as the novel therapy in the identified high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912200     DOI: 10.1158/0008-5472.CAN-06-1213

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  104 in total

1.  Genome-wide expression and copy number analysis identifies driver genes in gingivobuccal cancers.

Authors:  Srikant Ambatipudi; Moritz Gerstung; Manishkumar Pandey; Tanuja Samant; Asawari Patil; Shubhada Kane; Rajiv S Desai; Alejandro A Schäffer; Niko Beerenwinkel; Manoj B Mahimkar
Journal:  Genes Chromosomes Cancer       Date:  2011-11-10       Impact factor: 5.006

Review 2.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

Review 3.  NF-kappaB in carcinoma therapy and prevention.

Authors:  Matthew Brown; Jonah Cohen; Pattatheyil Arun; Zhong Chen; Carter Van Waes
Journal:  Expert Opin Ther Targets       Date:  2008-09       Impact factor: 6.902

4.  Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer.

Authors:  Lei Huang; Odile David; Robert J Cabay; Klara Valyi-Nagy; Virgilia Macias; Rong Zhong; Barry Wenig; Lawrence Feldman; Ralph Weichselbaum; Michael T Spiotto
Journal:  Clin Cancer Res       Date:  2018-12-20       Impact factor: 12.531

5.  Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF.

Authors:  Meng Tong; Brandon Lloyd; Ping Pei; Susan R Mallery
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

6.  Gene expression profiles as markers of aggressive disease-EGFR as a factor.

Authors:  Christine H Chung; Joel Parker; Shawn Levy; Robbert J Slebos; Adam P Dicker; Ulrich Rodeck
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007       Impact factor: 7.038

7.  Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.

Authors:  Yasmine Haddad; Woonyoung Choi; David J McConkey
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

8.  Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN.

Authors:  Martin Leinung; Daniel Hirth; Aykut Tahtali; Marc Diensthuber; Timo Stöver; Jens Wagenblast
Journal:  Oncol Lett       Date:  2012-09-20       Impact factor: 2.967

9.  Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma.

Authors:  Jarosław Markowski; Tomasz Tyszkiewicz; Michał Jarzab; Małgorzata Oczko-Wojciechowska; Tatiana Gierek; Małgorzata Witkowska; Jarosław Paluch; Małgorzata Kowalska; Zbigniew Wygoda; Dariusz Lange; Barbara Jarzab
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-07-16       Impact factor: 2.503

10.  The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas.

Authors:  Zhong Chen; Bin Yan; Carter Van Waes
Journal:  Biomark Med       Date:  2008       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.